BioIMeD
BioIMeD is an Italian medical device startup based in Trieste that builds AI-based products for disease diagnosis and monitoring — BiopIA, an automated liquid biopsy device using computer vision, and DomotIA, a remote patient monitoring platform offered as a service to hospitals and clinicians.
- Company typePrivate
- Founded2022
- HeadquartersTrieste, Italy
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioIMeD does
BioIMeD (legally Bio IMeD S.r.l.) is an Italian medical device startup founded around 2019 and headquartered in Trieste that develops AI-based products for disease diagnosis, treatment, and monitoring. The company sells two flagship products to healthcare providers, hospitals, anatomopathologists, and local health authorities: BiopIA, an automated liquid biopsy device that integrates microfiltration, a microfluidic chip, precision sensors, optical imaging, and machine learning software to acquire and analyze blood samples with claimed 90% diagnostic accuracy, 100% cellular recovery, and a 10x reduction in analysis time; and DomotIA, a remote patient monitoring platform offered as Infrastructure as a Service, which uses IoT sensors, cloud computing, and AI-based anomaly detection for continuous monitoring of elderly and chronic disease patients.
The technology stack combines proprietary hardware (microfluidic consumables, optical acquisition systems) with in-house computer vision and anomaly detection AI algorithms, the latter optimized by a dedicated computer engineering sub-team. BioIMeD's commercial model is direct sales of BiopIA devices to hospitals and clinical laboratories, paired with a managed-services IaaS offering for DomotIA; both go to market through direct channels, exclusively in Italy. Validation has been pursued through a clinical trial at Trieste's Cattinara Hospital and an announced research collaboration with Fondazione Italiana Fegato for liver disease applications, and the company holds a European patent application for the integrated BiopIA architecture.
The company's capital base is thin — approximately €39,550 raised via a 2019 POR FESR 2014-2020 grant — with a six-member multidisciplinary team spanning biomedical device engineering, clinical/regulatory affairs, and academic scientific leadership (Prof. Agostino Accardo as CSO). BioIMeD has received multiple Italian innovation awards (2019 StartCup FVG, Premio Nazionale Innovazione, AIIC special Healthcare Innovation recognition, Contamination Cup) and completed a CSA STAR Level 1 cloud security self-assessment in October 2022. No commercial revenue or subsequent funding rounds have been disclosed.
BioIMeD firmographics
Firmographics- Name
- BioIMeD
- Legal name
- Bio IMeD S.r.l.
- Website
- https://bioimed.it
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioIMeD is an Italian medical device startup based in Trieste that builds AI-based products for disease diagnosis and monitoring — BiopIA, an automated liquid biopsy device using computer vision, and DomotIA, a remote patient monitoring platform offered as a service to hospitals and clinicians.
- Ownership category
- akta.pro rank
BioIMeD industry classification
Industry- Product category
- Diagnostic Medical Devices
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Medical Imaging AI (HDAAAEAH)
Keywords
Where BioIMeD is headquartered
LocationHeadquarters
- HQ city
- Trieste
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
BioIMeD business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales (BiopIA): Sale of automated liquid biopsy diagnostic devices to hospitals, laboratories, and healthcare facilities. Two versions are being developed: a laboratory version for use with optical microscopes and a standalone version with integrated optics.
- DomotIA Platform (IaaS): Remote patient monitoring platform offered as Infrastructure as a Service (IaaS) to healthcare providers and systems, enabling continuous monitoring of chronic disease patients
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
BioIMeD product offering
Product offeringCore offering
BioIMeD develops AI-based intelligent medical devices that combine microfiltration, microfluidics, precision optical sensors, and machine learning software for diagnostic and monitoring applications. The company sells two main product lines: BiopIA, an automated liquid biopsy device for cancer diagnosis that delivers 100% cellular recovery and 90% diagnostic accuracy with over 10x reduction in analysis time, and DomotIA, an IoT-based remote patient monitoring platform offered as IaaS (Infrastructure as a Service) to healthcare systems.
Product overview
BioIMeD develops two main AI-based medical device products: BiopIA, an automated liquid biopsy device that combines microfiltration, microfluidic chips, precision sensors, optical imaging, and AI software to isolate and identify cancer cells from blood samples, achieving approximately 90% diagnostic accuracy and 100% cellular recovery while reducing analysis time by over 10x; and DomotIA, a remote IoT-based patient monitoring platform for healthcare operators and patients that collects continuous sensor data, processes it through cloud algorithms to detect anomalous behaviors, and delivers real-time alerts via web and mobile applications.
Differentiator
Problem solved
Functional benefit
Brands
- DomotIA: Remote domotic system for patient monitoring based on IoT solutions for healthcare operators and patients. Sensors collect patient data, cloud computing stores and analyzes data, web and mobile applications make data accessible to doctors and patients.
- BiopIA
Products and services
- BiopIA
Quantifiable outcome
- 90% diagnostic accuracy demonstrated during clinical trials
- +5 more outcomes
Companies that use BioIMeD
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
BioIMeD technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
BioIMeD partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Ospedale Cattinara di TriestecoreClinical trial partnership for testing the BiopIA liquid biopsy device. The hospital conducted initial tests and trials with promising results, achieving approximately 90% diagnostic accuracy. This partnership provided critical validation data for the device's performance.
- Fondazione Italiana FegatocoreUpcoming research collaboration for device testing. BioIMeD will soon start new projects together with Fondazione Italiana Fegato to expand clinical validation of the BiopIA device in liver disease diagnostics.
- CLab - Università degli Studi di TriesteminorEntrepreneurship program that nurtured the company's founding. The startup idea emerged during Simone Pennini's participation in the CLab program, where initial concept development and business mentorship occurred.
- Diego Sardon (Business Mentor)minorBusiness mentor and advisor, former CEO of Prodigys Technology and Bilimetrix. Joined the team to provide business expertise and network connections that helped advance the startup's development and partnerships.
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
BioIMeD competitors and assessment
Company assessmentDirect peers
- bioMérieux: bioMérieux operates FilmArray and other molecular diagnostic instrument lines for clinical and industrial microbiology, with growing oncology exposure. Directly comparable to BiopIA as a manufacturer of automated clinical diagnostic instruments combining sample prep, optics, and algorithmic interpretation.
- Cepheid (Danaher): Cepheid's GeneXpert system is the leading fully automated molecular diagnostic platform used in hospitals globally, including oncology and infectious disease assays. Directly comparable to BiopIA in pursuing cartridge-based, fully automated diagnostic workflow for clinical labs.
- Bio-Techne: Bio-Techne's Diagnostics & Genomics segment includes liquid-biopsy reagents (ExoDx), instruments, and analytical platforms used by clinical labs. Directly comparable to BiopIA in the liquid biopsy reagent/instrument market targeting clinical pathology customers.
- QIAGEN: QIAGEN provides sample-preparation kits and circulating-tumor-cell / cell-free-DNA liquid biopsy technologies plus automation platforms (QIAcube, QIAsymphony). Directly comparable to BiopIA in supplying liquid biopsy workflows and lab automation consumables to molecular pathology labs.
- Biofourmis: Biofourmis is an AI-driven remote patient monitoring and virtual care platform for chronic disease management. Directly comparable to DomotIA in combining IoT, cloud, and AI algorithms to detect clinical deterioration and trigger interventions for chronic and post-acute patients.
- Tunstall Healthcare: Tunstall provides telecare, telehealth, and remote patient monitoring solutions including ambient assisted living, primarily to European health and social care providers. Directly comparable to DomotIA in selling technology-enabled continuous monitoring services into European public health authorities.
- Biocartis: Biocartis develops the Idylla molecular diagnostic platform, an automated cartridge-based system for oncology and liquid biopsy testing. Directly comparable to BiopIA in that both target integrated, sample-to-result automation in molecular oncology diagnostics for hospital laboratories.
Regional players
- Menarini Diagnostics: Menarini Diagnostics is an Italy-headquartered diagnostic and medical device manufacturer distributing point-of-care and laboratory instrumentation across Europe. Comparable as a same-country diagnostics platform targeting Italian hospital laboratories, though it operates across a much broader product portfolio than BioIMeD.
Broad incumbents
- GRAIL: GRAIL is a well-capitalized liquid biopsy company developing multi-cancer early detection tests (Galleri). Tangentially comparable to BiopIA because both target blood-based cancer detection, but GRAIL operates at the assay/clinic level rather than as an instrument manufacturer and represents the competitive end-product on BioIMeD's installed base.
Emerging players
- Guardant Health: Guardant Health is a liquid biopsy specialist focused on circulating tumor DNA for oncology diagnostics. Partial overlap with BiopIA: both operate in cancer liquid biopsy, but BioIMeD builds the automation hardware platform rather than the assay itself.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
BioIMeD social profiles
Digital presenceBioIMeD compliance and trust
Trust signalCompliance1 record
BioIMeD financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioIMeD leadership team
Management profileNumber of profiles
Profiles6 records
BioIMeD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioIMeD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioIMeD
What does BioIMeD do?
BioIMeD develops AI-based intelligent medical devices that combine microfiltration, microfluidics, precision optical sensors, and machine learning software for diagnostic and monitoring applications. The company sells two main product lines: BiopIA, an automated liquid biopsy device for cancer diagnosis that delivers 100% cellular recovery and 90% diagnostic accuracy with over 10x reduction in analysis time, and DomotIA, an IoT-based remote patient monitoring platform offered as IaaS (Infrastructure as a Service) to healthcare systems.
Is BioIMeD a public or private company?
BioIMeD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioIMeD founded?
BioIMeD was founded in 2022. It employs 1 to 10 people.
Where is BioIMeD based?
BioIMeD is headquartered in Trieste, Italy, in the Europe region.
How does BioIMeD make money?
Two revenue lines are on record. Medical Device Sales (BiopIA) is the primary driver. The others are domotIA Platform (IaaS).
Who are BioIMeD's main competitors?
Direct peers on record are bioMérieux, Cepheid (Danaher), Bio-Techne, QIAGEN, Biofourmis, Tunstall Healthcare and Biocartis. Menarini Diagnostics is listed as a regional player. GRAIL is listed as a broad incumbent. Guardant Health is listed as an emerging player.
Does BioIMeD have an API?
No public API is recorded for BioIMeD.
What industry is BioIMeD in?
BioIMeD's product category is Diagnostic Medical Devices. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 334516 and its SIC code is 2835.